IQVIA Holdings Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. The filing also reports unaudited fourth-quarter results. Amounts below are in U.S. dollars; financial statement amounts are in millions unless stated otherwise.
Business context
IQVIA provides healthcare data, analytics and technology, clinical research services, and contract sales and medical services, primarily to life sciences companies. It operates through Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, with approximately 70,000 employees in more than 100 countries.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Revenue | $11,359 | $11,088 |
| Income from operations | $731 | $777 |
| Net income attributable to IQVIA | $279 | $191 |
| Diluted EPS | $1.43 | $0.96 |
| Cash from operating activities | $1,959 | $1,417 |
| Capital expenditures | $616 | $582 |
| Cash and cash equivalents at year-end | $1,814 | $837 |
| Total debt at year-end | $12,600 | $11,705 |
Revenue increased 2.4%, while operating income fell 5.9%. Operating margin was approximately 6.4%, compared with 7.0% in 2019; net income attributable to IQVIA was approximately 2.5% of revenue, versus 1.7%. Operating cash flow less capital expenditures was approximately $1,343 million, up from $835 million. The filing attributes the cash flow increase mainly to improved collections, higher advanced billings, and timing of tax and other payables.
Year-end current assets were $5,090 million and current liabilities were $4,558 million (current ratio approximately 1.12). The company reported $1.5 billion of revolving credit capacity with no amounts drawn at year-end, and $60 million available under its receivables financing facility. Management stated that available cash, expected operating cash flow and borrowing capacity were expected to fund requirements and debt obligations for at least the next 12 months. Debt increased by $895 million year over year.
Fourth-quarter results and segment trends
| Fourth-quarter metric | Q4 2020 | Q4 2019 |
|---|---|---|
| Revenue | $3,298 | $2,895 |
| Income from operations | $289 | $166 |
| Net income attributable to IQVIA | $119 | $16 |
| Diluted EPS | $0.61 | $0.09 |
For the full year, Technology & Analytics Solutions revenue rose 8.3% to $4,858 million and segment profit rose 10.4% to $1,216 million. Research & Development Solutions revenue declined 0.5% to $5,760 million and segment profit fell 8.2% to $1,048 million. Contract Sales & Medical Solutions revenue declined 9.0% to $741 million, while segment profit increased to $57 million from $52 million.
Material changes, outlook and risks
- COVID-19: The pandemic disrupted on-site clinical monitoring, site access, trial recruitment and face-to-face commercial activity. Clinical and lab activity declines were partly offset by vaccine and therapy trials; Technology & Analytics Solutions grew, particularly in real-world and analytical services. Contract sales activity was pressured by fewer sales-representative visits. Management reported gradual improvement in clinical-site access and expected delayed trial work to support momentum as the crisis subsided, while noting uncertainty about the pandemic’s duration and effects.
- Backlog: Research & Development Solutions contracted backlog grew to $22.6 billion from $19.0 billion. Approximately $5.9 billion was expected to convert to revenue in the next 12 months. Backlog is not guaranteed revenue; customers may cancel, delay or change project scope.
- Costs and unusual items: Depreciation and amortization rose to $1,287 million, partly due to acquired intangible assets and accelerated depreciation on internal-use software. Restructuring costs were $52 million; remaining actions were expected through 2021. The company recorded a $13 million loss on extinguishment of debt and a $26 million tax benefit associated with electing the GILTI high-tax exception. Lower interest rates and debt refinancing reduced interest expense compared with 2019.
- Debt and rates: The company issued €711 million of 2.875% notes due 2028, using proceeds in part to redeem 3.5% notes due 2024, and borrowed additional term A loans during 2020. Variable-rate exposure, debt covenants, refinancing needs and the transition away from LIBOR remain risks. The company was in material compliance with debt covenants at year-end.
- Principal risks: COVID-19 disruption; contract cancellations and cost overruns; dependence on third-party data; privacy, cybersecurity and regulatory compliance; competition and technology change; acquisition integration; foreign exchange and tax uncertainty; and substantial indebtedness. The filing identifies estimating costs to complete clinical research contracts—and the related revenue recognized over time—as a critical audit matter.
- Legal matters: The filing describes ongoing South Korean privacy-related proceedings and litigation with Veeva, including Veeva counterclaims seeking damages in excess of $200 million. Management did not expect pending legal and tax matters, individually or in aggregate, to have a material adverse effect, but noted an unfavorable outcome could be material in the period resolved.
Management discussed expected industry growth and strategic investment in analytics, virtual trials, technology and acquisitions, but the filing does not provide specific company revenue or earnings guidance for 2021.
Important facts for investors to verify
- Whether the strong Q4 results and increased R&D backlog convert into sustained revenue and profit, given project timing and cancellation risks.
- Whether margin pressure in Research & Development Solutions and continued weakness in Contract Sales & Medical Solutions persist after pandemic-related disruption.
- Debt repayment and refinancing capacity, variable-rate exposure, covenant headroom, and the effect of the LIBOR transition.
- Assumptions used to estimate clinical-contract costs to complete, which affect revenue recognition and were the auditor’s critical audit matter.
- Developments in the South Korean privacy cases and Veeva litigation, including potential financial or operational consequences.